SEC Form 4 · accession 0001127602-17-032178
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Milligan
Officer — President and CEO · Director
Period of report
Nov 13, 2017
Accepted (ET)
Nov 15, 2017 · 3:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 13, 2017 | M | 220,000 | $21.575 | A | 1,385,924 | D | |
| Common StockF2 | Nov 13, 2017 | S | 220,000 | $72.8849 | D | 1,165,924 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F3 | $21.575 | Nov 13, 2017 | M | 220,000 | D | — | Jan 30, 2018 | Common Stock | 220,000 | 0 | D |
Explanation of responses
- F1The exercise and sale transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2Sale prices reported for the transactions reported here range from $72.5201 to $73.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the Issuer or its shareowners upon request.
- F3The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013.